To develop a novel TB multi-organoid (lung, lymph node and liver) chip-based model for screening of candidate vaccines and treatment modalities

• Duration: October 2022 – September 2025
• Funded by the Gates Foundation
• Partnered by TBVI
• 3 partners

The goal of the TissUseTB project is to develop a human lung-liver-lymph node organoid co-culture chip capable of screening tuberculosis (TB) vaccine candidates and treatment modalities.

The establishment of the chip-based human multi-organoid lung-liver-lymph node co-culture for TB vaccine and treatment assessment will be performed at TissUse (Berlin, Germany) and the emulating of the TB infection of the chip-based model is conducted by the Institute of Pharmacology and Structural Biology (IPBS) of CNRS (Toulouse, France). The project is facilitated by TBVI.

Previous human chips developed by TissUse (HUMIMIC) have been successfully commercialized and adopted for use. The ability to screen TB vaccine candidates in such a human model system would be beneficial to the field, especially since currently no predictive animal models for TB are available.